The APP Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the amyloid precursor protein (APP) gene in the HT29 human colon adenocarcinoma cell line. This pooled polyclonal format provides a heterogeneous population of cells with targeted perturbation of APP expression, enabling loss-of-function studies without clonal selection artifacts. The product is designed for researchers investigating APP biology in epithelial tumor contexts.
HT29 cells are an established model of human colorectal adenocarcinoma, originally isolated from a primary tumor. These cells exhibit epithelial morphology, express colonocyte markers such as MUC2 and CDX2, and harbor mutations in key oncogenes and tumor suppressors, including TP53. Their well-characterized growth properties and capacity for spontaneous differentiation under certain culture conditions make them a versatile platform for dissecting molecular mechanisms in colorectal cancer.
APP is a type I transmembrane glycoprotein that undergoes sequential proteolytic processing by ??- or ??-secretase and ??-secretase. This processing generates soluble ectodomains (sAPP??/sAPP??), amyloid-?? (A??) peptides, and the APP intracellular domain (AICD). AICD can translocate to the nucleus, where it associates with the Fe65 adaptor protein and the histone acetyltransferase Tip60 to modulate transcription of target genes, including GSK3?? and presenilin-1. APP processing is tightly regulated by interacting factors such as low-density lipoprotein receptor-related protein 1 (LRP1), Disabled-1 (Dab1), X11/Mint, Reelin, ADAM10, BACE1, and the ??-secretase complex components presenilin-1, nicastrin, PEN-2, and APH-1. Upstream, APP expression is transcriptionally controlled by SP1, p53, NF-??B, HIF1A, and nerve growth factor signaling. Downstream, A?? peptides accumulate in Alzheimer??s disease, and AICD influences tau phosphorylation, caspase-3 activation, and PI3K-Akt signaling.
In HT29 colon cancer cells, APP has been implicated in cell adhesion, proliferation, and Wnt pathway modulation. APP can stabilize ??-catenin and promote Wnt signaling, contributing to the tumorigenic phenotype. Disruption of APP in this background is expected to attenuate these oncogenic properties, potentially reducing cell proliferation, migration, and resistance to apoptosis. Moreover, crosstalk with Notch signaling may further influence epithelial-to-mesenchymal transition (EMT) and stemness features, making this knockout model a valuable tool for dissecting APP??s tumor-promoting functions and its interplay with the oncogenic pathways intrinsic to colorectal cancer.
This polyclonal knockout model is suited for a wide range of experimental applications. It can be employed to study APP??s role in colon cancer pathogenesis through proliferation assays, transwell migration, and anchorage-independent growth experiments. In Alzheimer??s disease research, these cells serve as a tool for evaluating ??-secretase modulators and assessing A?? peptide production by ELISA. Moreover, they enable investigation of Notch and Wnt signaling interplay, characterization of APP interactomes via co-immunoprecipitation and mass spectrometry, and transcriptomic profiling by RNA-seq. Researchers can combine this model with representative assays such as western blotting for full-length APP and cleavage fragments, immunofluorescence for subcellular localization, and RT-qPCR for gene expression changes. For detailed product information and technical support, please contact Ascent Research.
